Update of research on the role of EZH2 in cancer progression.
Update of research on the role of EZH2 in cancer progression.
复制标题
DOI：
10.2147/ott.s42453
复制
发表时间：
2013
影响因子：
4
通讯作者：
Liu P
中科院分区：
文献类型：
--
作者：
Shen L;Cui J;Liang S;Pang Y;Liu P
越来越多的证据表明，zeste 同源物增强子 2 (E2H2) 在多种癌症类型中表达上调，例如乳腺癌、前列腺癌、卵巢癌和结肠癌。因此，抑制EZH2表达可能是一种有前景的抗癌治疗策略。本综述重点关注目前对参与癌症进展的 EZH2 调控机制的理解。此外，它还引入了两种针对 EZH2 的 EZH2 抑制剂，未来可能应用于癌症治疗。
Accumulating evidence shows that enhancer of zeste homolog 2 (E2H2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.